Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ioflupane i-123
Drug ID BADD_D01179
Description Ioflupane (I-123) is a radiopharmaceutical used to image dopamine neurons and diagnose Parkinsonian syndromes.
Indications and Usage Ioflupane I-123 is a SPECT (single photon emission computerized tomography) agent used to distinguish between Parkinson’s syndrome tremors and essential tremor.
Marketing Status approved
ATC Code Not Available
DrugBank ID DB08824
KEGG ID Not Available
MeSH ID C087552
PubChem ID 3086674
TTD Drug ID D02GJZ
NDC Product Code 17156-210; 69945-166
UNII 3MM99T8R5Q
Synonyms 2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane | beta-CIT-FP | N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iodophenyl)tropane | FP-CIT | FPCIT | (O-methyl-11C)beta-CIT-FP | fluoropropylcarbomethoxyiodophenylnortropane | I(123)-N-omega-fluoropropyl-2-beta-carbomethoxy-3-beta(4-iodophenyl)nortropane | I(123)-N-fluoropropyl-2-beta-carbomethoxy-3-(4-iodophenyl)nortropane | (18F)FP-CIT | 123I-FP-CIT
Chemical Information
Molecular Formula C18H23FINO2
CAS Registry Number 155798-07-5
SMILES COC(=O)C1C2CCC(N2CCCF)CC1C3=CC=C(C=C3)I
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001-Not Available
Burning sensation17.02.06.001; 08.01.09.029-Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Drug ineffective08.06.01.006-Not Available
Dry mouth07.06.01.002--
Dysgeusia17.02.07.003; 07.14.03.001--
Ear disorder04.03.01.001--Not Available
Feeling cold08.01.09.008-Not Available
Formication19.10.04.002; 17.02.06.018--Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Headache17.14.01.001--
Hyperhidrosis23.02.03.004; 08.01.03.028-
Hyperkalaemia14.05.03.001-
Hypersensitivity10.01.03.003--
Immune system disorder10.02.01.001--Not Available
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Injection site pain08.02.03.010; 12.07.03.011-Not Available
Nausea07.01.07.001--
Neoplasm malignant16.16.01.001--Not Available
Nervous system disorder17.02.10.001--Not Available
Pain08.01.08.004-
Paraesthesia23.03.03.094; 17.02.06.005--
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.007-
Malnutrition14.03.02.004--Not Available
Inner ear disorder04.04.02.002--Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.004-
The 1th Page    1    Total 1 Pages